Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

41. Canadian treatment guidelines on psychosocial treatment of schizophrenia in adults

Canadian treatment guidelines on psychosocial treatment of schizophrenia in adults 28703017 2017 07 13 2017 09 09 1497-0015 62 9 2017 Sep Canadian journal of psychiatry. Revue canadienne de psychiatrie Can J Psychiatry Canadian Treatment Guidelines on Psychosocial Treatment of Schizophrenia in Adults. 617-623 10.1177/0706743717719894 It is generally recognised that psychosocial interventions are essential components of the effective treatment of schizophrenia in adults. A considerable body (...) employment programs, and cognitive-behavioural therapy. There are also reasons to recommend the use of cognitive remediation, social skills training, and life skills training under specified circumstances. It is important that all patients and families be provided with education about the nature of schizophrenia and its treatment. Several recent innovative psychosocial approaches to treatment are awaiting more thorough evaluation. There continues to be strong evidence for the effectiveness of several

CMA Infobase (Canada)2017 Full Text: Link to full Text with Trip Pro

42. Canadian treatment guidelines on psychosocial treatment of schizophrenia in children and youth

Canadian treatment guidelines on psychosocial treatment of schizophrenia in children and youth 28886670 2017 09 09 2017 09 09 1497-0015 62 9 2017 Sep Canadian journal of psychiatry. Revue canadienne de psychiatrie Can J Psychiatry Canadian Treatment Guidelines on Psychosocial Treatment of Schizophrenia in Children and Youth. 648-655 10.1177/0706743717720195 A panel of experts, including researchers, clinicians and people with lived experience, was brought together to develop the new Canadian (...) schizophrenia guidelines for the psychosocial treatment of children and youth with schizophrenia or psychotic disorders. The ADAPTE process, which relies on adapting existing high-quality guidelines, was used. Existing guidelines for children and youth (mostly from the National Institute for Health and Care Excellence [NICE]), as well as CPA adult guidelines, were reviewed and discussed in terms of their adaptability to the Canadian context and their level of recommendation for children and youth. New

CMA Infobase (Canada)2017 Full Text: Link to full Text with Trip Pro

43. Guidelines for the pharmacotherapy of schizophrenia in adults

Guidelines for the pharmacotherapy of schizophrenia in adults 28703015 2017 07 13 2017 09 09 1497-0015 62 9 2017 Sep Canadian journal of psychiatry. Revue canadienne de psychiatrie Can J Psychiatry Guidelines for the Pharmacotherapy of Schizophrenia in Adults. 604-616 10.1177/0706743717720448 The present guidelines address the pharmacotherapy of schizophrenia in adults across different stages, phases, and symptom domains. Guidelines were developed using the ADAPTE process, which takes advantage (...) of existing guidelines. Six guidelines were identified for adaptation, with recommendations extracted from each. For those specific to the pharmacotherapy of schizophrenia in adults, a working group selected between guidelines and recommendations to create an adapted guideline. Recommendations can be categorized into 6 areas that include 1) first-episode schizophrenia, 2) acute exacerbation, 3) relapse prevention and maintenance treatment, 4) treatment-resistant schizophrenia, 5) clozapine-resistant

CMA Infobase (Canada)2017 Full Text: Link to full Text with Trip Pro

44. Physical health and drug safety in individuals with schizophrenia

Physical health and drug safety in individuals with schizophrenia 28718324 2017 07 18 2017 09 09 1497-0015 62 9 2017 Sep Canadian journal of psychiatry. Revue canadienne de psychiatrie Can J Psychiatry Physical Health and Drug Safety in Individuals with Schizophrenia. 673-683 10.1177/0706743717719898 While antipsychotic medications are the mainstay of therapy for individuals with schizophrenia and psychotic disorders, their use is associated with adverse effects on physical health that require (...) . Teehan Michael M 4 Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia. Ismail Zahinoor Z 5 Department of Psychiatry and Clinical Neurosciences, University of Calgary, Calgary, Alberta. Gardner David D 6 Department of Psychiatry and College of Pharmacy, Dalhousie University, Halifax, Nova Scotia. eng Journal Article 2017 07 18 United States Can J Psychiatry 7904187 0706-7437 ECG changes antipsychotic polypharmacy extrapyramidal symptoms metabolic syndrome schizophrenia 2017 7 19 6 0

CMA Infobase (Canada)2017 Full Text: Link to full Text with Trip Pro

45. Canadian guidelines for the assessment and diagnosis of patients with schizophrenia spectrum and other psychotic disorders

Canadian guidelines for the assessment and diagnosis of patients with schizophrenia spectrum and other psychotic disorders 28730847 2017 07 21 2017 09 09 1497-0015 62 9 2017 Sep Canadian journal of psychiatry. Revue canadienne de psychiatrie Can J Psychiatry Canadian Guidelines for the Assessment and Diagnosis of Patients with Schizophrenia Spectrum and Other Psychotic Disorders. 594-603 10.1177/0706743717719899 The objective of this article is to identify best practices in the diagnosis (...) and assessment of patients with schizophrenia spectrum and other psychotic disorders. The diagnosis and assessment may occur in a range of situations from the emergency room to the outpatient clinic and at different stages of the disorder. The focus may be on acute exacerbations of illness, residual symptoms, levels of function, or changes in the response to treatment. A systematic search was conducted for guidelines published in the last 5 years for schizophrenia and schizophrenia spectrum disorders

CMA Infobase (Canada)2017 Full Text: Link to full Text with Trip Pro

46. Quality of Care and Outcomes of Heart Failure Among Patients With Schizophrenia in Denmark

Quality of Care and Outcomes of Heart Failure Among Patients With Schizophrenia in Denmark 28774428 2017 08 04 2017 09 01 2017 09 01 1879-1913 120 6 2017 Sep 15 The American journal of cardiology Am. J. Cardiol. Quality of Care and Outcomes of Heart Failure Among Patients With Schizophrenia in Denmark. 980-985 S0002-9149(17)31035-4 10.1016/j.amjcard.2017.06.027 Research on the association between schizophrenia and the quality of care and clinical outcomes of heart failure (HF) remains sparse (...) . This nationwide study compared the quality of care and clinical outcomes of HF among Danish patients with and without schizophrenia. In a population-based cohort study, we identified 36,718 patients with incident HF with hospital contacts, including 108 with schizophrenia, using Danish registries between 2004 and 2013. High quality of HF care was defined as receiving ≥ 80% guideline-recommended process-performance measures of care. Potential predictors of HF care among patients with schizophrenia included

EvidenceUpdates2017

47. Latuda (lurasidone) - schizophrenia

Latuda (lurasidone) - schizophrenia Latuda (lurasidone) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Latuda (lurasidone) Conclusion Latuda contains lurasidone, which is a 2nd generation antipsychotic authorised for the treatment of schizophrenia in adults aged 18 years and over. Lurasidone efficacy in the PANSS total score is on a par with other 2nd generation antipsychotics, but has been demonstrated to be different from the other antipsychotics (...) , there are minimal effects on metabolic parameters as well as the QT interval. A line of antipsychotics with a similar efficacy profile are already sold on the market as generic products, which makes them significantly cheaper than Latuda. It is IRF's overall assessment that Latuda should not be a first-line treatment for schizophrenia in adults, but it could be relevant in cases where the minimisation of metabolic and cardiovascular effects is of utmost importance or in patients who are extremely concerned

Danish Pharmacotherapy Reviews2017

48. Three-month Injectable Paliperidone Palmitate for the Treatment of Adults with Schizophrenia: A Review of Clinical Effectiveness, Safety, and Guidelines

Three-month Injectable Paliperidone Palmitate for the Treatment of Adults with Schizophrenia: A Review of Clinical Effectiveness, Safety, and Guidelines Three-month Injectable Paliperidone Palmitate for the Treatment of Adults with Schizophrenia: A Review of Clinical Effectiveness, Safety, and Guidelines | CADTH.ca Find the information you need Three-month Injectable Paliperidone Palmitate for the Treatment of Adults with Schizophrenia: A Review of Clinical Effectiveness, Safety, and Guidelines (...) Three-month Injectable Paliperidone Palmitate for the Treatment of Adults with Schizophrenia: A Review of Clinical Effectiveness, Safety, and Guidelines Published on: August 31, 2017 Project Number: RC0917-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness and safety of 3-month injectable paliperidone palmitate for the treatment of adults with schizophrenia? What are the evidence-based guidelines

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

49. Postinjection delirium/sedation syndrome in patients with schizophrenia receiving olanzapine long-acting injection: results from a large observational study

Postinjection delirium/sedation syndrome in patients with schizophrenia receiving olanzapine long-acting injection: results from a large observational study 28811926 2018 11 13 2056-4724 3 4 2017 Jul BJPsych open BJPsych Open Postinjection delirium/sedation syndrome in patients with schizophrenia receiving olanzapine long-acting injection: results from a large observational study. 186-192 10.1192/bjpo.bp.116.004382 Postinjection delirium/sedation syndrome (PDSS) has been reported uncommonly (...) during treatment with olanzapine long-acting injection (LAI), a sustained-release formulation of olanzapine. The primary aim of the study was to estimate the incidence per injection and per patient of PDSS events in adult patients with schizophrenia who were receiving olanzapine LAI in real-world clinical practice. Secondary aims were to further characterise the clinical presentation of PDSS events, to identify potential risk factors associated with PDSS events and to characterise hospitalisations

BJPsych open2017 Full Text: Link to full Text with Trip Pro

50. Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial

Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial 28601891 2017 06 11 2017 07 19 2017 07 19 2168-6238 74 7 2017 Jul 01 JAMA psychiatry JAMA Psychiatry Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial. 719-728 10.1001 (...) /jamapsychiatry.2017.1220 Compared with the general population, patients with schizophrenia have a 2- to 3-fold higher mortality rate primarily caused by cardiovascular disease. Previous interventions designed to counteract antipsychotic-induced weight gain and cardiometabolic disturbances reported limited effects. To determine the effects of the glucagon-like peptide-1 receptor agonist liraglutide added to clozapine or olanzapine treatment of schizophrenia spectrum disorders. This randomized clinical double

EvidenceUpdates2017

51. Coronary heart disease risk in patients with schizophrenia: a Lebanese cross-sectional study

Coronary heart disease risk in patients with schizophrenia: a Lebanese cross-sectional study 29090191 2018 11 13 2235-042X 7 1 2017 Journal of comorbidity J Comorb Coronary heart disease risk in patients with schizophrenia: a Lebanese cross-sectional study. 79-88 10.15256/joc.2017.7.107 Coronary heart disease (CHD) is a leading cause of premature death in patients with schizophrenia. CHD risk in Lebanese patients with schizophrenia remains unknown. To (i) evaluate CHD risk of patients (...) with schizophrenia in Lebanon; and (ii) detect the modifiable and non-modifiable factors affecting this risk. Cross-sectional study of 329 patients with schizophrenia aged 20-75 years. Ten-year hard CHD risk was calculated using the Framingham risk score. A logistic regression was conducted taking the dichotomous hard CHD (<10% and ≥10%) as the dependent variable. Ten-year hard CHD risk was low (<10%) in 60.8% of patients, intermediate (10-20%) in 31.6%, and high (>20%) in 7.6%. Multivariate analysis showed

Journal of comorbidity2017 Full Text: Link to full Text with Trip Pro

52. Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence

Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence 28514486 2017 05 17 2017 07 05 2168-6238 74 7 2017 Jul 01 JAMA psychiatry JAMA Psychiatry Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence. 675-684 10.1001/jamapsychiatry.2017.0624 Limited (...) treatment responses in schizophrenia prompted the testing of combining an antipsychotic drug treatment with a second psychotropic medication. A comprehensive evaluation of the efficacy of multiple medication combinations is missing. To summarize and compare the meta-analytically determined efficacy of pharmacologic combination strategies of antipsychotic drugs in adults with schizophrenia. Systematic search of PubMed and PsycInfo until May 13, 2016. Meta-analyses of randomized clinical trials comparing

EvidenceUpdates2017

53. Clozapine dose for schizophrenia.

Clozapine dose for schizophrenia. BACKGROUND: Schizophrenia and related disorders such as schizophreniform and schizoaffective disorder are serious mental illnesses characterised by profound disruptions in thinking and speech, emotional processes, behaviour and sense of self. Clozapine is useful in the treatment of schizophrenia and related disorders, particularly when other antipsychotic medications have failed. It improves positive symptoms (such as delusions and hallucinations) and negative (...) symptoms (such as withdrawal and poverty of speech). However, it is unclear what dose of clozapine is most effective with the least side effects. OBJECTIVES: To compare the efficacy and tolerability of clozapine at different doses and to identify the optimal dose of clozapine in the treatment of schizophrenia, schizophreniform and schizoaffective disorders. SEARCH METHODS: We searched the Cochrane Schizophrenia Group's Study-Based Register of Trials (August 2011 and 8 December 2016). SELECTION CRITERIA

Cochrane2017

54. Lumateperone for acute exacerbations of psychosis in schizophrenia

Lumateperone for acute exacerbations of psychosis in schizophrenia Lumateperone for acute exacerbations of psychosis in schizophrenia ‐ NIHR Innovation Observatory ☰ Menu Search Filter by Specialty Filter by Year Lumateperone for acute exacerbations of psychosis in schizophrenia May 2017 Technology Description: Lumateperone is a new, orally administered antipsychotic drug which alters levels of several chemicals in the brain including dopamine, serotonin and glutamate. Studies (...) on lumateperone in people with schizophrenia experiencing an episode of severe symptoms suggest it may reduce symptoms with less side effects than current antipsychotic medication. If licensed lumateperone may provide an alternative treatment option for people with schizophrenia which may cause fewer side effects. Specialty You may also be interested in: Sep 2012 Specialty: Jun 2012 Specialty: Sep 2011 Specialty: Please answer these 2 questions to proceed to your free download Where are you based? England

NIHR Innovation Observatory2017

55. Increases in Intrinsic Thalamocortical Connectivity and Overall Cognition Following Cognitive Remediation in Chronic Schizophrenia

Increases in Intrinsic Thalamocortical Connectivity and Overall Cognition Following Cognitive Remediation in Chronic Schizophrenia 28584882 2018 11 13 2451-9030 2 4 2017 May Biological psychiatry. Cognitive neuroscience and neuroimaging Biol Psychiatry Cogn Neurosci Neuroimaging Increases in Intrinsic Thalamocortical Connectivity and Overall Cognition Following Cognitive Remediation in Chronic Schizophrenia. 355-362 10.1016/j.bpsc.2016.11.001 Thalamic projections to the prefrontal cortex (PFC (...) ) are critical for cognition, and disruptions in these circuits are thought to underlie the pathophysiology of schizophrenia. Cognitive remediation (REM) is a behavioral intervention that holds promise for improving cognition and functioning in schizophrenia, however the extent to which it affects thalamo-prefrontal connections has not been researched. This study sought to determine whether patients with schizophrenia who undergo a placebo-controlled trial of REM show increased functional connectivity

Biological psychiatry. Cognitive neuroscience and neuroimaging2017 Full Text: Link to full Text with Trip Pro

56. Impaired suppression of delay-period alpha and beta is associated with impaired working memory in schizophrenia

Impaired suppression of delay-period alpha and beta is associated with impaired working memory in schizophrenia 28670630 2018 11 13 2451-9030 2 3 2017 Apr Biological psychiatry. Cognitive neuroscience and neuroimaging Biol Psychiatry Cogn Neurosci Neuroimaging Impaired suppression of delay-period alpha and beta is associated with impaired working memory in schizophrenia. 272-279 10.1016/j.bpsc.2016.09.003 Although people with schizophrenia (PSZ) frequently exhibit reduced working memory (...) Steven J SJ Center for Mind and Brain, University of California, Davis. Gold James M JM Maryland Psychiatric Research Center, University of Maryland. eng R01 MH065034 MH NIMH NIH HHS United States T32 MH067533 MH NIMH NIH HHS United States Journal Article United States Biol Psychiatry Cogn Neurosci Neuroimaging 101671285 2451-9022 Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 Apr;2(3):212-213 29528291 EEG alpha suppression beta suppression schizophrenia visual working memory All other authors

Biological psychiatry. Cognitive neuroscience and neuroimaging2017 Full Text: Link to full Text with Trip Pro

57. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.

Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. BACKGROUND: Between 40% and 70% of people with treatment-resistant schizophrenia do not respond to clozapine, despite adequate blood levels. For these people, a number of treatment strategies have emerged, including the prescription of a second anti-psychotic drug in combination with clozapine. OBJECTIVES: To determine the clinical effects of various clozapine combination strategies with antipsychotic (...) drugs in people with treatment-resistant schizophrenia both in terms of efficacy and tolerability. SEARCH METHODS: We searched the Cochrane Schizophrenia Group's Study-Based Register of Trials (to 28 August 2015) and MEDLINE (November 2008). We checked the reference lists of all identified randomised controlled trials (RCT). For the first version of the review, we also contacted pharmaceutical companies to identify further trials. SELECTION CRITERIA: We included only RCTs recruiting people of both

Cochrane2017

58. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial.

Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. BACKGROUND: Although predominant negative symptoms of schizophrenia can be severe enough to cause persistent impairment, effective treatment options are lacking. We aimed to assess the new generation antipsychotic cariprazine in adult patients with predominant negative symptoms. METHODS: In this randomised, double-blind, phase 3b (...) trial, we enrolled adults aged 18-65 years with long-term (>2 year), stable schizophrenia and predominant negative symptoms (>6 months) at 66 study centres (mainly hospitals and university clinics, with a small number of private practices) in 11 European countries. Patients were randomly assigned (1:1) by an interactive web response system to 26 weeks of monotherapy with fixed-dose oral cariprazine (3 mg, 4·5 mg [target dose], or 6 mg per day) or risperidone (3 mg, 4 mg [target dose], or 6 mg

Lancet2017

59. Neurometabolic abnormalities in schizophrenia and depression observed with magnetic resonance spectroscopy at 7 T

Neurometabolic abnormalities in schizophrenia and depression observed with magnetic resonance spectroscopy at 7 T 28243459 2018 11 13 2056-4724 3 1 2017 Jan BJPsych open BJPsych Open Neurometabolic abnormalities in schizophrenia and depression observed with magnetic resonance spectroscopy at 7 T. 6-11 10.1192/bjpo.bp.116.003756 Examining neurometabolic abnormalities in critical brain areas in schizophrenia and major depressive disorder (MDD) may help guide future pharmacological interventions (...) including glutamate-modulating treatments. To measure metabolite concentrations within the anterior cingulate cortex (ACC) and thalamus of people with schizophrenia and people with MDD. Spectra were acquired from 16 volunteers with schizophrenia, 17 with MDD and 18 healthy controls using magnetic resonance spectroscopy on a 7 Tesla scanner. In the thalamus, there were lower glycine concentrations in the schizophrenia group relative to control ( P =0.017) and MDD groups ( P =0.012), and higher glutamine

BJPsych open2017 Full Text: Link to full Text with Trip Pro

60. Suicide and the unique prevalence pattern of schizophrenia in mainland China: a retrospective observational study.

Suicide and the unique prevalence pattern of schizophrenia in mainland China: a retrospective observational study. BACKGROUND: Unlike almost every other country in the world, the prevalence of both schizophrenia and suicide in China is higher in women than in men. Schizophrenia and suicide are important public-health problems for China that might be related to each other. We present prevalence data for schizophrenia and estimate relative and attributable risk of suicide in people (...) with schizophrenia in mainland China. METHODS: We used data from the national psychiatric epidemiology study, the Ministry of Health's mortality registry, the census, and the national psychological autopsy study to estimate frequencies and rates of schizophrenia, suicide, and suicide in people with schizophrenia aged 15 years and older in mainland China during 1995-99. FINDINGS: We estimated 4.25 million people with schizophrenia in China, and 284614 suicides and 28737 suicides in people with schizophrenia

Lancet2017